Acquisition of Expression of the *Pseudomonas aeruginosa* ExoU Cytotoxin Leads to Increased Bacterial Virulence in a Murine Model of Acute Pneumonia and Systemic Spread

MARKUS ALLEWELT,† FADIE T. COLEMAN, MARTHA GROUT, GREGORY P. PRIEBE, AND GERALD B. PIER*

Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115

Received 7 February 2000/Returned for modification 8 March 2000/Accepted 24 March 2000

*Pseudomonas aeruginosa* is the nosocomial bacterial pathogen most commonly isolated from the respiratory tract. Animal models of this infection are extremely valuable for studies of virulence and immunity. We thus evaluated the utility of a simple model of acute pneumonia for analyzing *P. aeruginosa* virulence by characterizing the course of bacterial infection in BALB/c mice following application of bacteria to the nares of anesthetized animals. Bacterial aspiration into the lungs was rapid, and 67 to 100% of the inoculum could be recovered within minutes from the lungs, with 0.1 to 1% of the inoculum found intracellularly shortly after infection. At later time points up to 10% of the bacteria were intracellular, as revealed by gentamicin exclusion assays on single-cell suspensions of infected lungs. Expression of exoenzyme U (ExoU) by *P. aeruginosa* is associated with a cytotoxic effect on epithelial cells in vitro and virulence in animal models. Insertional mutations in the exoU gene confer a noncytotoxic phenotype on mutant strains and decrease virulence for animals. We used the model of acute pneumonia to determine whether introduction of the exoU gene into noncytotoxic strains of *P. aeruginosa* lacking this gene affected virulence. Seven phenotypically noncytotoxic *P. aeruginosa* strains were transformed with pUCP19exoUspeU which carries the exoU gene and its associated chaperone. Three of these strains became cytotoxic to cultured epithelial cells in vitro. These strains all secreted ExoU, as confirmed by detection of the ExoU protein with specific antisera. The 50% lethal dose of exoU-expressing strains was significantly lower for all three *P. aeruginosa* isolates carrying plasmid pUCP19exoUspeU than for the isogenic exoU-negative strains. mRNA specific for ExoU was readily detected in the lungs of animals infected with the transformed *P. aeruginosa* strains. Introduction of the exoU gene confers a cytotoxic phenotype on some, but not all, otherwise-noncytotoxic *P. aeruginosa* strains and, for recombinant strains that could express ExoU, there was markedly increased virulence in a murine model of acute pneumonia and systemic spread.

*Pseudomonas aeruginosa* infection occurs when normal defense mechanisms are impaired or in cases of extensive tissue damage. Extracellular virulence factors including proteases, cytotoxins, phospholipases, pili, flagella, and smooth lipopolysaccharides have been shown to contribute to virulence in various animal models (18, 25, 26). Proteins exported by the type III secretion system, notably, exoenzyme S (ExoS), ExoT, and ExoU, have toxic effects on cells in culture (3, 7, 14, 24, 27, 28) and are thought to be important virulence factors of *P. aeruginosa*. Disruption of the pscC gene (a member of the secretin family of proteins needed for secretion of the exoenzyme proteins) by insertion of Tnl (29) reduced the virulence of cytotoxic strain PA 388 in burn wound infections in mice (18). This disruption did not affect levels of the mutant strain in a rat model of chronic lung infection, although there was a reduction in the amount of lung damage (19). In contrast, disruption of exoS in strain PA103 had no effect in a neonatal mouse model of acute pneumonia (26). With another cytotoxic and highly virulent *P. aeruginosa* strain, PA103, disruption of the exoU gene resulted in a loss of cytotoxicity and reduced virulence in a murine acute lung infection model (3), a finding also reported by Hauser et al. (10), who designated the gene as pepI in their study. In a related study, Kurahashi et al. (15) used a PA103 strain with an interrupted exoT gene and a deleted exoU gene and showed a loss of the ability of the strain to induce systemic inflammation and septic shock following installation into the lungs of rabbits. These authors concluded that in *P. aeruginosa* strains expressing ExoU the cytoxin may cause epithelial cell damage in the lung contributing to the subsequent release of inflammatory mediators into the systemic circulation that give rise to inflammation and septic shock.

These results clearly indicate that ExoU is an important virulence factor for *P. aeruginosa* strains that contain the gene and secrete the protein. However, not all clinical isolates of *P. aeruginosa* make ExoU (5, 11); thus, serious infection can develop without relying on this factor. An additional way to evaluate the role of a virulence factor such as ExoU in pathogenesis is to introduce the DNA for this protein into strains that lack it and determine whether there is a gain of virulence by the transformed strain. Evaluations of transformed strains for increased virulence can be hampered, however, if an appropriate animal model is not available with sufficient sensitivity to measure the increase in pathogenic capacity of the strains. To address these issues in the context of *P. aeruginosa* virulence and pathogenesis, we evaluated the phenotypic properties and virulence of noncytotoxic, exoU-negative strains of *P. aeruginosa* and isogenic strains transformed with DNA, allow-
ing for expression of the ExoU cytotoxin, in a simple model of acute pneumonia in mice. Application of *P. aeruginosa* to the nares of anesthetized mice resulted in rapid aspiration of most of the inoculum into the lungs, rapid internalization of a portion of the inoculum into lung cells, and death from acute pneumonia and sepsis within 24 to 48 h. Critically important, the model was highly sensitive to changes in virulence following transformation of three noncytotoxic *P. aeruginosa* strains with the *exoU* gene and its associated chaperon, with the ExoU-secreting transformants having dramatic reductions in 50% lethal dose (LD₅₀) values.

**MATERIALS AND METHODS**

**Bacterial strains.** Clinical isolates of *P. aeruginosa* from bacteremic patients were used to determine the presence of the *exoU* gene. Laboratory strain PA01 was originally obtained from Michael Usadel, Denver, Colo. Strain PAO6ad (Lanyi serogroup 60ad) was supplied by B. Lanyi, Budapest, Hungary (16), and the noncytotoxic corneal isolate, strain 6294, and the cytotoxic corneal isolate, strain 6077, were clinical isolates from patients with ulcerative keratitis.

**Vectors, determination of *exoU* in clinical isolates, and transformation of bacterial strains.** The *exoU* gene, its chaperone *spcU*, and flanking DNA were cloned by Frank and colleagues into plasmid pUCP19 to create plasmid pUCP19*exoUspcU*, which they kindly supplied for this study. The vector pUCP19 was also introduced into *P. aeruginosa* strains, and these transformed strains were used as controls. The clinical isolates of *P. aeruginosa* were tested for the presence of *exoU* by PCR. Chromosomal DNA was extracted from bacterial cells with the use of a commercial kit (QIAamp Tissue Kit: Qiagen, Valencia, Calif.). Then, 30 ng of DNA was used in a PCR reaction to detect a 428-bp internal sequence of *exoU* using primers 5'-GGGAACTATCTCCGGG AAGTT-3' and 5'-GCATTCTGCTGTAATGTTG-3'. The PCR reaction was performed using 32 cycles each of 90°C for 30 s, 59°C for 60 s, and 72°C for 90 s. Results were visualized by electrophoresis in a 1% agarose gel followed by ethidium bromide staining. *P. aeruginosa* strains negative for the *exoU* gene were then transformed with pUCP19 or the control plasmid pUCP19 by electroporation. Approximately 10¹⁸ CFU of bacteria were made electrocompetent, then transformed with pUCP19*exoUspcU* or the control plasmid pUCP19 by electroporation.

**Detection of ExoU protein in recombinant strains.** *P. aeruginosa* strains carrying the cloning vector or pUCP19*exoUspcU* were grown in LB broth supplemented with 10 mM nitrofurionic acid (Sigma) and 400 μg of carbenicillin/ml. Supernatants were recovered, proteins were precipitated by the addition of ammonium sulfate to a 55% (vol/vol) saturation final concentration, and the precipitate was recovered and dissolved in one-tenth the original volume, using PBS, and then dialyzed against PBS and used in an immun-dot blot assay as described earlier (13).

**In vitro cytotoxicity assay.** T84 colon carcinoma cells were maintained and passed at 37°C in 5% CO₂ in a 1:1 mixture of Dulbecco modified Eagle medium supplemented with 4.5 g of glucose and Ham's F-12 medium per liter, 5% nonessential activated fetal bovine serum, and 1% l-glutamine. Cell-adherent cells were cultured in 96-well plates (Falcon; Becton Dickinson, Franklin Lakes, N.J.) and used in experiments after a confluent monolayer had formed. After cells were washed once with phosphate-buffered saline (PBS), 200 μl of transformed *P. aeruginosa* strains at a concentration of approximately 10⁷ CFU/ml, suspended in a culture medium containing 400 μg of carbenicillin/ml, was added. Three wells of cells were used for each strain in each experiment. Control sauces were incubated with culture medium and carbenicillin alone. After incubation for 3 h, the medium was removed and the cell layer was washed once with PBS to remove most of the nonassociated bacteria. Then, 5 μl of trypsin blue was added for 90 s and removed, and the cells were washed once with PBS. The amount of cell damage was scored as follows: 0, no damage; 1, a score of 1 to 4, representing the amount of cytotoxicity exhibited by the *exoU*-positive cytotoxic *P. aeruginosa* strain 6077. The amount of cell damage caused by the nontoxic strain 6294 was represented by a score of 1. This method had been found to correlate well with the results of quantitative assessment by chromium release.

**Experimental pneumonia in mice.** Two murine models of acute *P. aeruginosa* pneumonia were used to evaluate pathogenesis. For bacterial inocula, transformed *P. aeruginosa* strains were grown on L agar containing 400 μg of carbenicillin/ml (i.e., with antibiotic). Wild-type clinical and laboratory strains were grown without additional antibiotic (i.e., without antibiotic). Bacteria from this plate were inoculated into LB broth ≤ 400 μg of carbenicillin/ml at an optical density at 650 nm (OD₆₅₀) of 0.1 and grown to an OD₆₅₀ of 0.5 with rotation at 37°C. Bacterial cultures were recovered by centrifugation and resuspended to an OD₆₅₀ of 0.4 in 1% protease peptone with 400 μg of carbenicillin/ml.

Infection of neonatal mice with *P. aeruginosa* by nasal application was performed as described previously (20, 21, 25). For adult mice, 6- to 8-week-old female C57BL/6 mice were anesthetized by intraperitoneal injection of a freshly prepared mixture of ketamine hydrochloride (65 mg/kg) and xylazine (13 mg/kg). With mice held in an upright position, 10 μl of a bacterial suspension was placed on each nostril (20 μl total). Animals were observed for survival for up to 72 h or sacrificed at various time periods up to 24 h after infection for determination of CFU in tissues. Lungs, spleen, and a 200- to 300-μg portion of the liver were surgically removed, weighed, and homogenized in 1 ml of proteose peptone on ice. Serial 10-fold dilutions were performed in 1% protease peptone, and 100 μl of diluted bacterial suspensions was plated on MacConkey agar plates at 37°C for 18 to 24 h. The resultant CFU were calculated as the level of bacterial infection per gram of homogenized tissue. For determination of intracellular *P. aeruginosa*, lungs were aseptically removed and single cell suspensions were made by homogenizing the tissue through a 100-μm and then through a tissue culture medium containing 300 μg of gentamicin/ml. Large tissue fragments were allowed to settle, and the suspended cells were pipetted into another tube and incubated in the antibiotic for 1 h at 37°C. The cells were washed twice and then resuspended in 150 μl of 0.5% Trypan blue. Intracellular bacteria, which were quantified by serial dilution and plating as described above. Student *t* tests were used for two-way comparisons of tissue levels of *P. aeruginosa*, and logistic regression for parallel bioassays was used to test for differences in the LD₅₀.

**Expression of ExoU in vivo.** BALB/c mice were challenged with 2 × 10⁸ of transformed bacteria as described above, and 24 h later animals were sacrificed, lungs were surgically removed and homogenized, and total RNA was extracted with a commercial kit (RNeasy; Qiagen). cDNA was transcribed with reverse transcriptase from 2 μg of total RNA (SuperScriptII; Gibco-BRL/Life Technologies, Rockville, Md.). A total of 30 ng of cDNA was added to a PCR reaction that included primers specific to *exoU* and identical to the ones mentioned above. cDNA was amplified at 94°C for 30 s, 59°C for 30 s, and 72°C for 60 s for a total of 35 cycles. Primers amplifying a 314-bp product (5'-CCGATTAGAGG TTCTTGGGT-3' and 5'-GAACGACGTCGCTGTTTAC-3') served as a control. DNA was separated on a 2% agarose gel and stained with ethidium bromide.

**RESULTS**

Characterization of the adult murine model of acute pneumonia. George et al. (8, 9) have previously used nasal application of *P. aeruginosa* in mice to evaluate bacterial virulence. Using a similar approach we initially characterized the model to assess its utility and sensitivity for the evaluation of *P. aeruginosa* virulence. Placement of 20 μl of bacterial suspen-
The inoculum for *P. aeruginosa* was applied to the nares of adult mice (Fig. 1). Recovery of the inoculum and the percentage of the inoculum that was recovered from the lungs is indicated above each pair of bars.

Comparisons were then made between noncytotoxic *P. aeruginosa* strain PAO1 and cytotoxic strain 6077 inoculated into murine noses at a dose determined in preliminary experiments to be just above that needed to kill all infected mice (Fig. 2). Comparisons of the total and internalized CFU/gram of lung tissue in mice sacrificed shortly after infection (time zero) or 3 or 6 h after infection showed progressive increases in bacterial levels in the tissue. There was evidence of rapid internalization of a portion of the *P. aeruginosa* inoculum, with up to 1% of the inoculum apparently intracellular, as evidenced by resistance to gentamicin killing in single-cell suspensions of lungs (Fig. 2) and up to 10% of the inoculum resistant to killing by gentamicin, and presumably intracellular, by 3 to 6 h (Fig. 2). Specific cell types ingesting the *P. aeruginosa* bacteria were not investigated. Spleens and livers were generally sterile in mice sacrificed prior to 6 h postinfection, but at this and subsequent time points *P. aeruginosa* was recovered in increasing numbers from these tissues (data not shown). We noted also that, in mice given a lethal inocula of *P. aeruginosa*, the levels of bacteria in the lungs and extrapulmonary tissues 6 h after infection were predictive of a lethal or nonlethal outcome: levels of *P. aeruginosa* in lungs of mice given lethal inocula and sacrificed at 6 h after infection were found to exceed the inocula (Fig. 2), and there was always evidence of extrapulmonary infection. In contrast, mice given sublethal inocula showed a decrease in the level of bacteria in the lung, compared with the initial inoculum, by 6 h after infection, and there was rarely evidence of extrapulmonary infection at this time (data not shown).

**Comparison of *P. aeruginosa* pathogenesis in neonatal and adult mice.** Tang et al. (25, 26) described the utility of application of *P. aeruginosa* into the nares of unanesthetized neonatal mice for evaluation of pathogenesis. However, in this model mortality was reported to range from 0 to 60% depending on the strain of *P. aeruginosa* used, while unanesthetized adult mice tolerated doses of up to $10^{10}$ CFU/mouse without effect (25). Thus, virulence in the neonatal mice is usually measured by the histologic appearance of lung tissue or by bacterial loads in tissues. Since it appeared that anesthetized adult mice manifested a greater degree of mortality following nasal application of *P. aeruginosa* than awake neonatal mice, we determined the CFU/gram of tissue and LD$_{50}$ in 7-day-old neonatal BALB/c mice. A smaller but nonetheless substantial proportion of the inoculum applied to the neonatal nares reached the lungs quickly (mean, $22.7 \pm 0.9\%$ for strain PAO1) than was seen with anesthetized adult mice (Fig. 1 and 2). However, the neonatal mice rapidly cleared inocula of *P. aeruginosa* strain PAO1 of $<2 \times 10^{8}$ CFU/mouse, and there was no mortality. Thus, anesthetized adult mice succumb more readily to *P. aeruginosa* infection than awake neonatal mice, a result likely due to the greater ability of *P. aeruginosa* to enter adult lungs following nasal application.

**Detection of exoU in clinical isolates of *P. aeruginosa*.** Among 14 clinical isolates of *P. aeruginosa*, 9 strains had the *exoU* gene, whereas in the other 5 there was no detectable *exoU* even after repeated PCR evaluations (Fig. 3). All five of these strains, as well as noncytotoxic strains PAO1 and PAO6ad, were transformed with plasmid pUCP19exoUspecU or pUCP19, and all recombinant strains contained the correct plasmid after...
transformation, as confirmed by plasmid extraction and restriction enzyme analysis.

Detection of cytotoxicity and expression of exoU in transformed P. aeruginosa strains. All transformed strains were tested for in vitro cytotoxic activity on T84 human colon carcinoma cells. Only three of the transformants, strains PAO1 (pUCP19exoUspcU), PA06ad(pUCP19exoUspcU), and 15921 (pUCP19exoUspcU) were cytotoxic. The other transformants containing pUCP19exoUspcU failed to show cytotoxic activity. The three recombinant, cytotoxic strains all expressed a protein in extracellular culture supernatants strongly reactive with the ExoU-specific antiserum (Fig. 4), whereas there was no reactive protein in any of the other strains carrying pUCP19 exoUspcU but lacking a cytotoxic phenotype (not shown). The three recombinant strains positive for ExoU expression by immuno-dot blot also had in their culture supernatants the appropriately sized 70-kDa band reactive with the ExoU-specific antiserum in a Western blot (not shown).

Evaluation of the role of ExoU in P. aeruginosa virulence. Pilot experiments comparing cytotoxic and noncytotoxic, nonisogenic strains of P. aeruginosa suggested that expression of ExoU enhanced bacterial virulence in the acute pneumonia model, as all cytotoxic strains tested (i.e., 6077 and 103) had LD_{50} values of <$5 \times 10^6$ CFU/mouse, whereas noncytotoxic strains generally had LD_{50} values at least 1 log higher. To formally evaluate the role of ExoU in virulence, the three pairs of cytotoxic and noncytotoxic P. aeruginosa strains isogenic for the plasmid containing the exoU gene and the cloning vector plasmid were inoculated at various doses onto the nares of anesthetized, adult BALB/c mice. Comparisons were made between the bacterial loads in the lung and extrapulmonary bacteremic spread after infection was established, and the LD_{50} values were determined. Groups of five animals each were sacrificed 18 to 24 h after infection. In all cases, the CFU/gram of lung tissue was significantly higher in the lungs of animals infected with P. aeruginosa carrying the exoU gene; data from animals infected with two doses of isogenic PAO1 are shown in Fig. 5. mRNA for the ExoU protein was detected by reverse transcription-PCR (RT-PCR) in the lungs of mice infected with P. aeruginosa carrying the exoU gene but not in

---

**FIG. 3.** Agarose gel stained with ethidium bromide showing the presence or absence of the 428-bp amplified exoU gene fragment in 14 clinical isolates of P. aeruginosa. Lanes: MW, molecular weight marker, 1, positive control pUCP19exoUspcU; 2, strain 45203; 3, strain 9156; 4, strain 56184; 5, strain Weaver; 6, strain 51921; 7, strain 1597; 8, strain Becker; 9, strain 29185; 10, strain 9882; 11, strain Rhodes; 12, strain 1947; 13, strain 9326; 14, strain 05074; 15, strain 3006.

**FIG. 4.** Immuno-dot blot of expression of recombinant ExoU protein in culture supernates of P. aeruginosa PAO1, 15921, and PAO6ad carrying either the control, vector plasmid pUCP19 (Vec), or the plasmid containing the exoU gene, pUCP19exoUspcU (ExoU).

**FIG. 5.** Comparison of CFU/gram of lung tissue 14 to 18 h after intranasal infection of anesthetized mice with isogenic P. aeruginosa PAO1(pUCP19) or PAO1(pUCP19exoUspcU). Bars indicate the means, and the error bars show the standard deviations. P values were determined by unpaired Student t tests.
the lungs of animals infected with *P. aeruginosa* lacking the exoU gene (Fig. 6). Extrapulmonary infection in the spleens and livers was routinely observed in animals given lethal doses of *P. aeruginosa* intranasally, e.g., infected livers and spleens were found in those mice inoculated with $>10^6$ CFU of *P. aeruginosa* strains carrying the exoU gene and $>5 \times 10^7$ CFU of strains lacking the exoU gene (not shown).

After application of various doses of cytotoxic and noncytotoxic transformed strains to groups of four or five animals and a follow-up period of 72 h to observe for death, the LD$_{50}$s were calculated and compared by logistic regression for parallel bioassays (Table 1). In all cases a significant increase in virulence was associated with expression of ExoU, in the range of 20- to $>50$-fold decreases in the LD$_{50}$. The LD$_{50}$ for *P. aeruginosa* strain 15921 lacking the exoU gene could not be calculated since there were insufficient deaths for an accurate LD$_{50}$ determination in mice given intranasal doses as high as $10^8$ CFU. When one considers that the LD$_{50}$ was lowered by 2 $\times 10^7$ to $9 \times 10^7$ CFU of *P. aeruginosa* for strains expressing ExoU (Table 1), the marked contribution of ExoU to *P. aeruginosa* virulence in this animal model can readily be appreciated.

![Image](https://via.placeholder.com/150)

TABLE 1. LD$_{50}$ values after 72 h of infection comparing three strains of *P. aeruginosa* carrying either pUCP19 or pUCP19exoUspcU after intranasal application to anesthetized mice

<table>
<thead>
<tr>
<th><em>P. aeruginosa</em> strain</th>
<th>Plasmid</th>
<th>LD$_{50}$ CFU</th>
<th>$p^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAO1</td>
<td>pUCP19</td>
<td>$2.8 \times 10^7$</td>
<td>0.047</td>
</tr>
<tr>
<td></td>
<td>pUCP19exoUspcU</td>
<td>$7.1 \times 10^6$</td>
<td></td>
</tr>
<tr>
<td>PAO6ad</td>
<td>pUCP19</td>
<td>$2.2 \times 10^7$</td>
<td>0.0001</td>
</tr>
<tr>
<td></td>
<td>pUCP19exoUspcU</td>
<td>$1.4 \times 10^6$</td>
<td></td>
</tr>
<tr>
<td>15921</td>
<td>pUCP19</td>
<td>$&gt;10^{16}$</td>
<td>0.0001</td>
</tr>
<tr>
<td></td>
<td>pUCP19exoUspcU</td>
<td>$3.6 \times 10^6$</td>
<td></td>
</tr>
</tbody>
</table>

$^a$ $p$ was determined by logistic regression for parallel bioassays.

$^b$ The LD$_{50}$ for 15921(pUCP19) could not be calculated since the maximal dose applied of $10^8$ CFU/mouse caused insufficient mortality.

**DISCUSSION**

We used and further characterized a murine model of acute *P. aeruginosa* pneumonia following application of bacteria to the nares of anesthetized animals and found that simply placing two 10-$\mu$l volumes of bacterial suspensions in each nostril resulted in a reliable and reproducible induction of pneumonia and systemic spread. Between 67 and 100% of the inoculated *P. aeruginosa* CFU were recovered from the lungs minutes after infection, and up to 1% of the inoculum was immediately taken up by respiratory cells, as evidenced by bacterial resistance to killing by gentamicin in single cell suspensions of infected lungs. The specific cells ingesting the *P. aeruginosa* were not determined, although phagocytes usually rapidly kill *P. aeruginosa* following ingestion (17). Lethal doses of *P. aeruginosa* resulted in increasing levels of bacteria in the lungs over a 24-h period and extrapulmonary spread to the spleen and liver by 6 h after infection. For ExoU-expressing strains, LD$_{50}$ values in the range of $10^5$ to $10^6$ CFU per mouse were determined, indicating that a fairly low *P. aeruginosa* inoculum can be applied to the noses of intact mice to achieve a lethal infection. The utility of this simple model, its sensitivity for measuring virulence properties for many *P. aeruginosa* strains, and its clear relevance to *P. aeruginosa* respiratory tract colonization and initial infection.

Comolli et al. (2) recently reported on the use of this model to measure the virulence of *P. aeruginosa* strains deficient in the pilT or pilU genes whose products contribute to the pilus-mediated twitching motility of this organism. Previously, Tang et al. (25) reported a reduction in virulence in the neonatal mouse model of pneumonia of mutant *P. aeruginosa* strains unable to produce pili. However, Comolli et al. (2) found no effect on either lung levels of *P. aeruginosa* or mortality from loss of the pilT or pilU genes but did find decreased levels of the mutant organism in the liver. As shown here, other extrapulmonary tissues such as the spleen are also infected, so the lower levels of the mutant strains in the liver found in the study of Comolli et al. (2) may merely have been due to a shift of the mutant strains toward infection of other tissues. As we found that extrapulmonary infection correlated with mortality, the lack of a difference in mortality between wild-type and pilT or pilU mutant strains suggests little role for pilus-mediated twitching motility in the dissemination of *P. aeruginosa* from the lung to extrapulmonary tissues in this mouse model.

The most striking results were obtained by comparing the virulence and lethality of *P. aeruginosa* strains isogenic for expression of the ExoU cytotoxin. In a small sample of 14 blood isolates, 5 did not have the exoU gene, but this small sample is not likely to be representative of clinical isolates of *P. aeruginosa*. When these five noncytotoxic strains were transformed with plasmid pUCP19exoUspcU, only one strain became cytotoxic and expressed ExoU. Two other noncytotoxic laboratory strains, PAO1 and PAO6ad, became cytotoxic when transformed with pUCP19exoUspcU. Thus, we had three isogenic strains for comparisons. The inability of some strains transformed with pUCP19exoUspcU to express ExoU is not understood at this time but may be due to the complexity of the type III secretion apparatus needed to export ExoU. When the three noncytotoxic strains of *P. aeruginosa* that could be complemented to a cytotoxic phenotype with the exoU gene were compared for virulence and LD$_{50}$ values, strains carrying the exoU gene exhibited a statistically significant enhanced virulence. This finding confirms the previous work of Finck-Bar-
bancon et al. (3), Hauser et al. (10), and Wiener-Kronish and colleagues (15), who used P. aeruginosa strains with an interrupted exoU gene to document a role in virulence for this factor. Our work extends these findings by showing that transformation of P. aeruginosa with pUCP19exoUspcU can confer cytotoxicity due to ExoU expression on some strains and can also result in a significant gain of virulence when evaluated in an acute lung infection model of mice. Taken together, these findings all suggest that, when expressed, ExoU plays an important role in virulence of P. aeruginosa. However, it must also be appreciated that numerous clinical isolates of P. aerugi-


van August 15, 2017 by guest http://iai.asm.org/ Downloaded from


Editor: E. I. Tuomanen